Stroke is the second highest cause of death globally and a leading cause of disability, with
an increasing incidence in develo** countries. Ischaemic stroke caused by arterial …

Objectives: Concise “synthetic” review of the state of the art of management of acute
ischemic stroke. Data Sources: Available literature on PubMed. Study Selection: We …

Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

Background Thrombolytic agents, including tenecteplase, are generally used within 4.5
hours after the onset of stroke symptoms. Information on whether tenecteplase confers …

Stroke is the leading cause of long term disability in developed countries and one of the top
causes of mortality worldwide. The past decade has seen substantial advances in the …

Executive summary Stroke is the second leading cause of death worldwide. The burden of
disability after a stroke is also large, and is increasing at a faster pace in low-income and …

Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

Abstract EDITOR'S NOTE The article “Update on Treatment of Acute Ischemic Stroke” by Dr
Rabinstein was first published in the February 2017 Cerebrovascular Disease issue of …

The treatment of acute ischemic stroke continues to advance. The mainstay of treatment
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …

Tenecteplase is a fibrinolytic drug with higher fibrin specificity and longer half-life than the
standard stroke thrombolytic, alteplase, permitting the convenience of single bolus …